Lancet:GWAS研究发现哮喘与多基因风险有关

2013-07-24 青楚 lancet

美国学者的一项研究显示,哮喘多基因风险与哮喘发作及其过程相关。相关论文2013年6月28日在线发表于《柳叶刀》(Lancet)杂志。 该前瞻性纵向研究从全基因组相关研究(GWAS)发表的关于哮喘的案例中得到了多种遗传风险因子。我们随后在一项人群为基础的长期出生队列(达尼丁多学科健康与发展研究,n=1037)中检测基因风险评分和哮喘发生和生物学特点之间的关系。使用哮喘发作、哮喘持续、过敏性

美国学者的一项研究显示,哮喘多基因风险与哮喘发作及其过程相关。相关论文2013年6月28日在线发表于《柳叶刀》(Lancet)杂志。

该前瞻性纵向研究从全基因组相关研究(GWAS)发表的关于哮喘的案例中得到了多种遗传风险因子。我们随后在一项人群为基础的长期出生队列(达尼丁多学科健康与发展研究,n=1037)中检测基因风险评分和哮喘发生和生物学特点之间的关系。使用哮喘发作、哮喘持续、过敏性疾病、气道高反应性、不完全可逆的气流阻塞和哮喘相关的学校或工作缺勤、9项9-38岁人群前瞻性评估得到的入院资料等做分析。

结果显示,在我们分析的880例患者中,与基因风险低者相比,哮喘发病基因风险高者更早发病(危险比为1.12, 95% CI为1.01—1.26). 在儿童发作哮喘的患者中,基因风险高者比基因风险低者更易发生持久性哮喘(相关比为1.36, 95% CI为1.14—1.63)。与基因风险低者相比,哮喘基因风险高者更常发生过敏性疾病(RR 1.07, 95% CI为1.01—1.14)、气道高反应性(RR 1.16, 95% CI为1.03—1.32), 和不完全可逆的气流阻塞(RR 1.28, 95% CI为1.04—1.57)。他们更容易因为哮喘发生缺课、缺勤(发生率比为1.38, 95% CI为1.02—1.86)或住院(HR 1.38, 95% CI为1.07—1.79) 。关于哮喘风险的多基因信息独立于队列成员哮喘家族史。


Dr Daniel W Belsky Corresponding AuthorEmail Address, Prof Malcolm R Sears , Robert J Hancox , HonaLee Harrington, Renate Houts, Prof Terrie E Moffitt, Karen Sugden, Benjamin Williams, Prof Richie Poulton, Prof Avshalom Caspi ;Polygenic risk and the development and course of asthma: an analysis of data from a four-decade longitudinal study; The Lancet Respiratory Medicine, Early Online Publication, 28 June 2013 doi:10.1016/S2213-2600(13)70101-2   

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1827602, encodeId=ba53182e6027d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Nov 26 23:50:00 CST 2013, time=2013-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949759, encodeId=eadd1949e59ab, content=<a href='/topic/show?id=b1ec431e5ab' target=_blank style='color:#2F92EE;'>#多基因风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43175, encryptionId=b1ec431e5ab, topicName=多基因风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c49e75, createdName=qjddjq, createdTime=Tue Jun 10 23:50:00 CST 2014, time=2014-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754428, encodeId=8d231e54428f5, content=<a href='/topic/show?id=44e2431e1c6' target=_blank style='color:#2F92EE;'>#多基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43171, encryptionId=44e2431e1c6, topicName=多基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b34b36693912, createdName=syscxl, createdTime=Sun Mar 02 23:50:00 CST 2014, time=2014-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704489, encodeId=f76b1e04489eb, content=<a href='/topic/show?id=1f5b41931ce' target=_blank style='color:#2F92EE;'>#基因风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41931, encryptionId=1f5b41931ce, topicName=基因风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb0530750602, createdName=hmwwww, createdTime=Fri Jan 10 04:50:00 CST 2014, time=2014-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753009, encodeId=df571e530093f, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sun Dec 15 07:50:00 CST 2013, time=2013-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280026, encodeId=abbe1280026bc, content=<a href='/topic/show?id=b05983454a' target=_blank style='color:#2F92EE;'>#GWAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8345, encryptionId=b05983454a, topicName=GWAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Fri Jul 26 09:50:00 CST 2013, time=2013-07-26, status=1, ipAttribution=)]
    2013-11-26 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1827602, encodeId=ba53182e6027d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Nov 26 23:50:00 CST 2013, time=2013-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949759, encodeId=eadd1949e59ab, content=<a href='/topic/show?id=b1ec431e5ab' target=_blank style='color:#2F92EE;'>#多基因风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43175, encryptionId=b1ec431e5ab, topicName=多基因风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c49e75, createdName=qjddjq, createdTime=Tue Jun 10 23:50:00 CST 2014, time=2014-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754428, encodeId=8d231e54428f5, content=<a href='/topic/show?id=44e2431e1c6' target=_blank style='color:#2F92EE;'>#多基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43171, encryptionId=44e2431e1c6, topicName=多基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b34b36693912, createdName=syscxl, createdTime=Sun Mar 02 23:50:00 CST 2014, time=2014-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704489, encodeId=f76b1e04489eb, content=<a href='/topic/show?id=1f5b41931ce' target=_blank style='color:#2F92EE;'>#基因风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41931, encryptionId=1f5b41931ce, topicName=基因风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb0530750602, createdName=hmwwww, createdTime=Fri Jan 10 04:50:00 CST 2014, time=2014-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753009, encodeId=df571e530093f, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sun Dec 15 07:50:00 CST 2013, time=2013-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280026, encodeId=abbe1280026bc, content=<a href='/topic/show?id=b05983454a' target=_blank style='color:#2F92EE;'>#GWAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8345, encryptionId=b05983454a, topicName=GWAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Fri Jul 26 09:50:00 CST 2013, time=2013-07-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1827602, encodeId=ba53182e6027d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Nov 26 23:50:00 CST 2013, time=2013-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949759, encodeId=eadd1949e59ab, content=<a href='/topic/show?id=b1ec431e5ab' target=_blank style='color:#2F92EE;'>#多基因风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43175, encryptionId=b1ec431e5ab, topicName=多基因风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c49e75, createdName=qjddjq, createdTime=Tue Jun 10 23:50:00 CST 2014, time=2014-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754428, encodeId=8d231e54428f5, content=<a href='/topic/show?id=44e2431e1c6' target=_blank style='color:#2F92EE;'>#多基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43171, encryptionId=44e2431e1c6, topicName=多基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b34b36693912, createdName=syscxl, createdTime=Sun Mar 02 23:50:00 CST 2014, time=2014-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704489, encodeId=f76b1e04489eb, content=<a href='/topic/show?id=1f5b41931ce' target=_blank style='color:#2F92EE;'>#基因风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41931, encryptionId=1f5b41931ce, topicName=基因风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb0530750602, createdName=hmwwww, createdTime=Fri Jan 10 04:50:00 CST 2014, time=2014-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753009, encodeId=df571e530093f, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sun Dec 15 07:50:00 CST 2013, time=2013-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280026, encodeId=abbe1280026bc, content=<a href='/topic/show?id=b05983454a' target=_blank style='color:#2F92EE;'>#GWAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8345, encryptionId=b05983454a, topicName=GWAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Fri Jul 26 09:50:00 CST 2013, time=2013-07-26, status=1, ipAttribution=)]
    2014-03-02 syscxl
  4. [GetPortalCommentsPageByObjectIdResponse(id=1827602, encodeId=ba53182e6027d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Nov 26 23:50:00 CST 2013, time=2013-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949759, encodeId=eadd1949e59ab, content=<a href='/topic/show?id=b1ec431e5ab' target=_blank style='color:#2F92EE;'>#多基因风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43175, encryptionId=b1ec431e5ab, topicName=多基因风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c49e75, createdName=qjddjq, createdTime=Tue Jun 10 23:50:00 CST 2014, time=2014-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754428, encodeId=8d231e54428f5, content=<a href='/topic/show?id=44e2431e1c6' target=_blank style='color:#2F92EE;'>#多基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43171, encryptionId=44e2431e1c6, topicName=多基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b34b36693912, createdName=syscxl, createdTime=Sun Mar 02 23:50:00 CST 2014, time=2014-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704489, encodeId=f76b1e04489eb, content=<a href='/topic/show?id=1f5b41931ce' target=_blank style='color:#2F92EE;'>#基因风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41931, encryptionId=1f5b41931ce, topicName=基因风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb0530750602, createdName=hmwwww, createdTime=Fri Jan 10 04:50:00 CST 2014, time=2014-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753009, encodeId=df571e530093f, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sun Dec 15 07:50:00 CST 2013, time=2013-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280026, encodeId=abbe1280026bc, content=<a href='/topic/show?id=b05983454a' target=_blank style='color:#2F92EE;'>#GWAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8345, encryptionId=b05983454a, topicName=GWAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Fri Jul 26 09:50:00 CST 2013, time=2013-07-26, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1827602, encodeId=ba53182e6027d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Nov 26 23:50:00 CST 2013, time=2013-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949759, encodeId=eadd1949e59ab, content=<a href='/topic/show?id=b1ec431e5ab' target=_blank style='color:#2F92EE;'>#多基因风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43175, encryptionId=b1ec431e5ab, topicName=多基因风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c49e75, createdName=qjddjq, createdTime=Tue Jun 10 23:50:00 CST 2014, time=2014-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754428, encodeId=8d231e54428f5, content=<a href='/topic/show?id=44e2431e1c6' target=_blank style='color:#2F92EE;'>#多基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43171, encryptionId=44e2431e1c6, topicName=多基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b34b36693912, createdName=syscxl, createdTime=Sun Mar 02 23:50:00 CST 2014, time=2014-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704489, encodeId=f76b1e04489eb, content=<a href='/topic/show?id=1f5b41931ce' target=_blank style='color:#2F92EE;'>#基因风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41931, encryptionId=1f5b41931ce, topicName=基因风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb0530750602, createdName=hmwwww, createdTime=Fri Jan 10 04:50:00 CST 2014, time=2014-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753009, encodeId=df571e530093f, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sun Dec 15 07:50:00 CST 2013, time=2013-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280026, encodeId=abbe1280026bc, content=<a href='/topic/show?id=b05983454a' target=_blank style='color:#2F92EE;'>#GWAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8345, encryptionId=b05983454a, topicName=GWAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Fri Jul 26 09:50:00 CST 2013, time=2013-07-26, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1827602, encodeId=ba53182e6027d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Nov 26 23:50:00 CST 2013, time=2013-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949759, encodeId=eadd1949e59ab, content=<a href='/topic/show?id=b1ec431e5ab' target=_blank style='color:#2F92EE;'>#多基因风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43175, encryptionId=b1ec431e5ab, topicName=多基因风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c49e75, createdName=qjddjq, createdTime=Tue Jun 10 23:50:00 CST 2014, time=2014-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754428, encodeId=8d231e54428f5, content=<a href='/topic/show?id=44e2431e1c6' target=_blank style='color:#2F92EE;'>#多基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43171, encryptionId=44e2431e1c6, topicName=多基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b34b36693912, createdName=syscxl, createdTime=Sun Mar 02 23:50:00 CST 2014, time=2014-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704489, encodeId=f76b1e04489eb, content=<a href='/topic/show?id=1f5b41931ce' target=_blank style='color:#2F92EE;'>#基因风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41931, encryptionId=1f5b41931ce, topicName=基因风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb0530750602, createdName=hmwwww, createdTime=Fri Jan 10 04:50:00 CST 2014, time=2014-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753009, encodeId=df571e530093f, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sun Dec 15 07:50:00 CST 2013, time=2013-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280026, encodeId=abbe1280026bc, content=<a href='/topic/show?id=b05983454a' target=_blank style='color:#2F92EE;'>#GWAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8345, encryptionId=b05983454a, topicName=GWAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Fri Jul 26 09:50:00 CST 2013, time=2013-07-26, status=1, ipAttribution=)]
    2013-07-26 lxg951

相关资讯

抗胆碱能药物噻托溴铵治疗中度至重度哮喘存在争议

  近期,发表于Journal of Allergy and Clinical Immunolog上的一篇综述总结了长效抗胆碱能药物在哮喘治疗中的应用。作者提到,使用抗胆碱药物维持治疗慢性阻塞性肺疾病(COPD)是公认的。然而使用抗胆碱能药物治疗中度至重度哮喘仍然是一个有争议的点。   早期病例报告和小规模的研究评估使用抗胆碱能药物噻托溴铵在哮喘

CHEST:成年支气管哮喘患者的死亡率明显增加

对于诊断明确的支气管哮喘(哮喘)患者而言,其相关的长期随访研究数据目前比较有限。为了加深对这一问题的认识,来自丹麦哥本哈根大学哈维德夫医院肺内科的Charlotte Suppli Ulrik及其同事进行了一项研究,研究结果在线发表于2013年3月7日的《CHEST》杂志上。该研究结果显示:与相匹配的对照组相比,诊断明确的成年哮喘患者的死亡率增加,而且这种增加在很大程度上,可以用继发于哮喘的阻塞性肺

哮喘管理:未来的路在何方?

      阳春三月,名院名家面对面国际讲者巡讲暨重庆国际哮喘论坛在重庆隆重召开,中外哮喘专家就当前哮喘领域的学术热点进行了交流,英国安特里胸部医院(Aintree Chest Centre)哮喘领域学术带头人罗伯特·安格斯(Robert&nb

心电图案例分析:哮喘发作

  1例支气管哮喘中年女性患者,无冠心病与心肌梗死史,此次因哮喘发作记录左图。      心电图解析与诊断   1. 窦性心律并Ⅰ度房室传导阻滞;   2. 肢体导联QRS波向量符合左前分支阻滞(LAH);   3. 多导联ST-T改变性质待定;   4. V1~V2导联心室波起始向量呈低振幅qr

赛诺菲旗下哮喘药物Dupilumab中期试验结果令人惊喜

研究人员于5月21日声称,一款以治疗呼吸疾病根本病因为目的新型哮喘药物在一项中期临床试验中能够使哮喘发作减少87%,对于中度至重度哮喘患者来说,该药物可能会成为一款开创性的药物。 Dupilumab是由Regeneron制药和赛诺菲开发的一款注射剂治疗药物,Dupilumab的这项临床试验有104名患者参与,其主要研究者莎莉·文策尔说:“总之,这是我们20年来在治疗哮喘方面所观察到的最令人激动的

走出哮喘激素治疗认知误区

  病例简介   患儿男性,15岁,哮喘反复发作6年。   患儿平时很少使用药物治疗控制哮喘,发作时才至医院接受输液治疗。近期曾因一次重症发作,被送至急诊抢救。   医师查阅该患儿既往门诊病历,可见其曾被多次建议应用吸入性糖皮质激素(ICS)或激素联合长效支气管扩张剂治疗。再三询问后得知,患儿父母认为长期应用激素有多种副作用,可能影响患儿生长发育,故未予患儿长期、规律的激素治疗,导致